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Four-year randomized prospective comparison of
percutaneous ePTFE/nitinol self-expanding stent
graft versus prosthetic femoral-popliteal bypass in
the treatment of superficial femoral artery
occlusive disease
Karen McQuade, MD,a Dennis Gable, MD,a Greg Pearl, MD,a Brian Theune, MD,b and
Steve Black, MSPH,a Dallas, Tex; and Fort Bragg, NC
Background: This is a randomized prospective study comparing the treatment of superficial femoral artery occlusive
disease percutaneously with an expanded polytetrafluoroethylene (ePTFE)/nitinol self-expanding stent graft (stent
graft) versus surgical femoral to above-knee popliteal artery bypass with synthetic graft material.
Methods: One hundred limbs in 86 patients with superficial femoral artery occlusive disease were evaluated from March
2004 to May 2005. Patient symptoms included both claudication and limb threatening ischemia with or without tissue
loss. Trans-Atlantic InterSociety Consensus (TASC II) A (n  18), B (n  56), C (n  11), and D (n  15) lesions were
included. Patients were randomized prospectively into one of two treatment groups; a percutaneous treatment group
(group A; n  50) with angioplasty and placement of one or more stent grafts, or a surgical treatment group (group B;
n  50) with a femoral to above-knee popliteal artery bypass using synthetic conduit (Dacron or ePTFE). Patients were
followed for 48 months. Follow-up evaluation included clinical assessment, physical examination, ankle-brachial indices,
and color flow duplex sonography at 3, 6, 9, 12, 18, 24, 36, and 48 months.
Results:Mean total lesion length of the treated arterial segment in the stent graft group was 25.6 cm (SD 15 cm). The stent
graft group demonstrated a primary patency of 72%, 63%, 63%, and 59%with a secondary patency of 83%, 74%, 74%, and 74%
at 12, 24, 36, and 48months, respectively. The surgical femoral-popliteal group demonstrated a primary patency of 76%, 63%,
63%, and 58% with a secondary patency of 86%, 76%, 76%, and 71% at 12, 24, 36, and 48 months, respectively. No statistical
difference was found between the two groups with respect to primary (P  .807) or secondary (P  .891) patency.
Conclusion: Management of superficial femoral artery occlusive disease with percutaneous stent grafts exhibits similar
primary patency at 4-year (48 month) follow up when compared with conventional femoral-popliteal artery bypass
grafting with synthetic conduit. This treatment method may offer an alternative to treatment of the superficial femoral
artery segment for revascularization when prosthetic bypass is being considered or when autologous conduit is
unavailable. ( J Vasc Surg 2010;52:584-91.)Lower extremity ischemia is often the result of vascular
disease in the superficial femoral artery (SFA). When revas-
cularization of the SFA is deemed necessary due to severe
atherosclerotic disease, vein bypass is still considered the
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584“gold standard.” If autologous venous conduit is unavail-
able, however, surgical options are limited to the use of
prosthetic material for femoral-popliteal above-knee by-
pass. Advances in endovascular therapy have provided new
options for treatment of disease in this region. Lesions
previously thought amenable only to open surgical bypass
can now be successfully managed percutaneously; however,
there remains great debate on the type of endovascular
treatment to be offered. We have previously published a
report on the current series with 24-month follow up,
demonstrating primary patency rates of 63% and 64% with
secondary patency rates of 74% and 76%, respectively, in
both a stent graft arm (n 50) and surgical arm (n 50).1
Multiple independent studies of the Viabahn (W.L. Gore,
Flagstaff, Ariz) stent graft platform in the SFA have dem-
onstrated comparable results.2-16 The purpose of our cur-
rent study was to compare the efficacy of the stent graft
versus open surgical prosthetic femoral to above-knee pop-
liteal bypass in a randomized prospective fashion for the
treatment of SFA occlusive disease with long term follow
up of 48 months.
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Study design. Our study design has been previously
published.1,17 Briefly, the study is a prospective, random-
ized trial carried out at a single institution between March
2004 and May 2005. The study was approved by the FDA
with an investigational device exemption (IDE) and was
approved and monitored by the hospital institutional re-
view board. All study participants signed an informed con-
sent agreement as part of the initial enrollment. Patients
with symptoms of lifestyle-altering claudication or rest pain
with or without tissue loss were evaluated for treatment.
Clinical exam and non-invasive studies (ankle-brachial in-
dices and color-flow duplex ultrasonography) were used to
confirm infra-inguinal disease. Patients considered for
treatment subsequently underwent digital subtraction an-
giography or computed tomography angiography to eval-
uate the location and extent of atherosclerotic disease.
Inclusion criteria consisted of patients with atheroscle-
rotic stenotic or occlusive lesions of the superficial femoral
artery with no significant aorto-iliac disease. The infra-
popliteal segment had to be patent with at least single vessel
run-off to the ankle. Patients had to be acceptable surgical
candidates in the event they were randomized to the surgi-
cal arm. Enrolled patients were prospectively randomized
by limb prior to intervention into one of two treatment
groups: percutaneous endovascular treatment with the
stent graft or open surgical femoral to above-knee popliteal
artery bypass with synthetic graft.
Study population. Between March 2004 and May
2005, a total of 100 limbs in 86 patients met the inclusion
criteria as described. Forty patients (50 limbs) were ran-
domized to treatment with the stent graft, and 46 patients
(50 limbs) were randomized to treatment with femoral to
above-knee popliteal artery bypass. The demographic data
and associated comorbidities are summarized in Table I.
Technique. Stent graft design as well as our open
surgical and endovascular technique have been previously
published.1,17 Femoral-popliteal bypass was performed in
the standard fashion. Patients in the endovascular arm were
accessed percutaneously in the common femoral artery via
standard Seldinger technique and were fully anticoagulated
with heparin (100 units/kg) during the procedure. Sub-
Table I. Patient demographics*
Stent graft grou
Mean age 72 (SD  9.9; ra
Male (no. of limbs) 32
Smoking history 22
Diabetes 14
Coronary artery disease 13
Hypertension 30
Hyperlipidemia 23
Chronic obstructive pulmonary disease 2
*Four patients randomized one limb to both treatment groups.
aTwo-tailed t-test with pooled variances.
bTwo-tailed Fisher’s exact test.intimal dissection was used to cross occlusive lesions withpre-dilatation angioplasty of the lesion to be treated then
being performed. Lesion length was recorded by in-plane
technique using amarking catheter. Stent graft deployment
was accomplished with stents being sized to vessel lumen
diameter. Post-deployment angioplasty molding was then
performed. After stent graft placement, patients were im-
mediately started on aspirin (81-325 mg/day) and clopi-
dogrel (75 mg/day) for a minimum of 3 months. Patients
receiving warfarin therapy for other associated conditions
prior to treatment were continued on the drug in addition
to aspirin 81 mg/day. Clopidogrel was not used in these
cases. After 3 months of treatment, anti-platelet therapy
was left to the discretion of the treating physician. An
identical anti-platelet regimen was instituted postopera-
tively for the surgical arm.
Postoperative assessment and follow-up examination.
Follow up included clinical exam, color flowDoppler ultra-
sound, and ankle brachial indices at 3, 6, 9, 12, 18, 24, 36,
and 48 months. Color flow Doppler ultrasound was per-
formed at an approved Intersocietal Commission for the
Accreditation of Vascular Laboratories (ICAVL) laboratory
and used to assess patency of grafts and to detect recurrent
arterial or graft stenosis. Primary and secondary patency
rates and graft failure rates were defined with the criteria
previously described by Ahn18 and Rutherford.19 Graft
failure was defined as stent graft/bypass thrombosis, reste-
nosis of 50% of the treated arterial segment immediately
above or below the stent graft/bypass graft (anastamotic or
stent landing zone sites), intra-stent/intra-graft restenosis
50%, or a decrease in the ankle-brachial index of 0.15 or
greater.
Statistical analysis. An independent statistician re-
viewed all submitted data and performed the correspond-
ing statistical calculations. The log-rank test was used to
calculate primary and secondary patency rates versus time of
follow up in Kaplan-Meier analysis as well as amputation
rates between the two treatment groups. A two-tailed t-test
with pooled variances and two-tailed Fisher’s exact test was
used to evaluate differences in patient demographics. The
Fisher’s exact test (generalized version for tables beyond
2  2) was used to evaluate differences in grades of chronic
limb ischemia pretreatment and inTrans-Atlantic InterSociety
 40) Surgical bypass group (n  46) P value
40-84) 67 (SD  10.7; range, 40-86) .033a
36 1.000b
27 .828b
20 .509b
22 .189b
42 .076b
21 .286b
8 .097bp (n
nge,Consensus (TASC II) classification. The Fisher’s general-
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vessels in each treatment arm and to evaluate the runoff
score comparison in each arm. A P-value 0.05 was con-
sidered statistically significant. The purpose of the study
was explorative to show the similarity of the mean estimates
and confidence intervals for the treatments along with the
P-value.
RESULTS
Fifty limbs in 40 patients were treated percutaneously
with the stent graft, and 50 limbs in 46 patients were
treated surgically with femoral above-knee popliteal artery
bypass. Classifications for all limbs as outlined by the TASC
II classification system for femoral-popliteal lesions20 are
shown in Table II. Pretreatment clinical categories of
chronic limb ischemia using Rutherford’s classification of
limb ischemia16 are shown in Table III (online only). No
significant difference was noted in TASC II classification or
in the pretreatment clinical limb ischemia between the two
treatment groups.
Run-off vessels and individual run-off scores were ret-
rospectively calculated for each limb and classified accord-
ing to Rutherford et al.21,22 Information on 98 of 100
limbs was available. In comparing the number of run-off
vessels between the endovascular arm and surgical arm, the
number of patients with one, two, or three runoff vessels
was evenly distributed with no statistical difference seen
(P  .902; Table IV). This was also true when comparing
the run-off scores between these same two treatment
groups (P  .487; Table V). When the stent graft group
alone is analyzed, comparing the smaller diameter stent
grafts (5 mm) to the larger stent grafts (6-7 mm), there is
no significant difference noted between the two groups for
number of run-off vessels (P  .157; Table VI [online
only]) or for run-off scores (P  .214; Table VII [online
Table II. Lesion TASC II classification per limb20
TASC Surgical bypass N  50 Stent graft N  50
A 8 10
B 27 29
C 5 6
D 10 5
Generalized Fisher’s exact test, P  .582.
Table IV. Comparison of number of run-off vessels by
treatment arm
Stent graft
Femoral-popliteal
bypass
Total
patients
1 13 11 24 (24.5%)
2 16 18 34 (34.7%)
3 21 19 40 (40.8%)
Total Patients 50 48 98 (100.0%)
Fisher’s exact test P  .902.only]). There is a trend towards more patients with onerun-off vessel in the 5 mm stent graft group; however, this
trend was not supported in the run-off score analysis.
Stent graft placement was technically successful in
100% of limbs in the stent graft group. A total of 114
devices were implanted in 50 limbs, with a mean of 2.3
stent grafts placed per limb. Mean diameter of the stent
grafts was 5.7 mm (range, 5-7 mm). Mean total length of
artery covered with the stent graft was 25.6 cm (SD15 cm).
Posttreatment, 37 (93%) of 40 patients in the stent graft
group took clopidogrel and aspirin for a minimum of 3
months. One patient claimed an allergy to clopidogrel,
while two other patients refused to take clopidogrel. These
three patients did take aspirin. Complications were noted in
4 of 40 patients (50 limbs; 8%) treated with the stent graft.
Immediate procedure-related and early postoperative, non-
thrombotic complications, as well as length of hospital stay,
is outlined in our previous series.1,17
Femoral to above-knee popliteal artery bypass was suc-
cessfully performed in 100% of limbs in the surgical group.
Dacron grafts were used in 32 limbs (64%), and ePTFE was
used in 18 limbs (36%). Mean diameter of the synthetic
bypass grafts was 7.4 mm (range, 7-8 mm). Twenty-four of
46 patients (52%) were on clopidogrel and aspirin post-
treatment for a minimum of 3 months. Seventeen patients
were on aspirin only, based on the recommendation of the
treating surgeon. The remaining five patients were on
warfarin preoperatively andwere continued on this regimen
postoperatively.
Complete 48-month follow up for patients was avail-
able in 32 (64%) of 50 limbs in the stent graft group. Nine
patients (18%) expired during the study period from con-
ditions unrelated to infra-inguinal disease (two with bilateral
limbs enrolled). Six patients (12%)were lost to follow-up (one
with bilateral limb enrollment). During follow up, a total of
18 of the stent grafts (36%) failed secondary to thrombosis.
Early graft thrombosis occurred in the recovery room the
same day of the procedure in one patient. One stent graft
thrombosis occurred within the first month after stent graft
implantation. The other 16 stent graft thromboses were
detected after a mean period of 11.3 months (SD  6
months) after placement. There was only one thrombotic
event in our patient cohort that occurred beyond 24-
month follow up. All three patients in the stent graft group
Table V. Run-off score by treatment arm
Run-off score Stent graft
Femoral-popliteal
bypass
Total
patients
1 21 16 37 (37.8%)
2 0 1 1 (1.0%)
3 0 2 2 (2.0%)
4 15 17 32 (32.7%)
5 0 1 1 (1.0%)
6 1 0 1 (1.0%)
7 13 11 24 (24.5%)
Total Patients 50 48 98 (100.0%)
Fisher’s exact test P  .487.that were not treated with clopidogrel posttreatment re-
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(24%) were TASC II B lesions. Of the remaining six throm-
bosed grafts, there were two each (4% each) of TASC II A,
C, and D lesions.
Of the 18 thrombosed grafts, five (29%) underwent
successful open mechanical balloon thrombectomy. One of
18 was successfully recanalized with intra-arterial mediated
lysis. In 11 of 18 cases (61%), attempts at thrombectomy or
lysis were unsuccessful, and these patients eventually under-
went open surgical bypass (seven to the above-knee popli-
teal artery; four to infra-geniculate vessels). Thirteen of
these failures were due to edge restenosis of the stent graft.
There was no in-stent restenosis seen in any of the patients.
In the four patients requiring bypass to the infra-geniculate
segment, progression of distal disease was the primary
mode of failure. Finally, one patient with a thrombosed
stent graft was found to have heparin-induced thrombocy-
topenia with no notable stent-related restenosis, and am-
putation eventually was performed due to progressive tissue
loss. This patient had minor tissue loss preoperatively.
Overall, 18 interventions had to be performed in the stent
graft treatment group during 48 months.
Complete 48 month follow-up was available for 26 of
50 limbs (52%) in the surgical bypass group. Eight patients
(16%; one with bilateral limbs) expired due to conditions
unrelated to their infra-inguinal disease. Fifteen (30%) pa-
tients were lost to follow up. There were 16 incidences
(32%) of synthetic graft failure. These included 15 graft
thrombosis and one graft that remained patent but was
considered a failure due to an anastamotic stenosis 50%.
Of the 15 thrombosed grafts (16 graft failures), ten (20%)
were TASC II B lesions, one (patent but with an anasta-
motic stenosis 50%) was TASC II C, and five (10%) were
TASC II D lesions. One graft thrombosis occurred within
the first month after implantation. The other 15 graft
failures were detected after a mean of 17 months (SD  8
months).
Five of the 15 thrombosed synthetic grafts (33.3%) were
successfully declotted with mechanical balloon thrombec-
tomy. One of these patients re-occluded at 48 months but
maintained a viable limb, and no further treatment has been
pursued. Three patients (20%) underwent below-knee pop-
liteal artery bypass with greater saphenous vein after throm-
bectomy failed. Two patients (13.3%) underwent a redo
femoral above-knee popliteal bypass with venous conduit.
One patient with a proximal anastomotic stenosis greater
than 50% was observed without intervention, and one
patient with a graft thrombosis remained with a viable limb
without further intervention being required. Six amputa-
tions were eventually required, but two of these patients
had patent grafts. Overall, 16 interventions had to be
performed in the surgical bypass group during 48 months.
The primary patency rate for the stent graft group at
12, 24, 36, and 48 months was 72%, 63%, 63%, and 59%,
respectively, while the primary patency for the surgical
bypass group was 76%, 63%, 63%, and 58%, respectively, as
seen in Fig 1 and Table VIII (online only). Secondary
patency at 12, 24, 36, and 48 months was 83%, 74%, 74%,and 74% for the stent graft group and 86%, 76%, 76%, and
71% for the surgical arm, respectively, as seen in Fig 2 and
Table IX (online only). There was no significant difference in
primary patency (P .807) or secondary patency (P .891)
between the two treatment groups. All limbs in the stent
Fig 1. Primary patency by treatment group.
Log-rank P value: P  .807.
Days 0 31 137 228 320 410 593 730 1095 1460
Stent graft 50 50 49 39 36 32 32 26 22 15
Femoral-
popliteal
bypass
50 50 45 41 33 32 30 27 25 12
Fig 2. Secondary patency by treatment group.
Log-rank P value: P  .891.
Days 0 31 137 228 320 410 593 730 1095 1460
Stent graft 50 50 50 41 38 37 37 31 27 16
Femoral-
popliteal
bypass
50 50 45 42 35 34 34 31 29 16graft treatment group (100%) and 46 limbs in the surgical
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Rutherford classification grade.19
Dividing the stent graft cohort into smaller diameter (5
mm) versus larger diameter (6-7 mm) groups, a trend
towards better patency in the larger diameter group is seen.
Although the design and power of the current series does
not allow for true statistical analysis in this regard, Fig 3
(online only) and Table X (online only) demonstrate that
the primary patency is improved in the larger stent graft
cohort at 24 and 48 months respectively (54% vs 69% at 24
months; 54% vs 62% at 48 months). These results do not
equate to any apparent statistical difference (P  .484; log
rank). The trend is further upheld with reported secondary
patency for these two groups, although again, there is no
statistical difference. Fig 4 (online only) and Table XI
(online only) demonstrate a secondary patency of 70% for
the 5 mm group at 24 and 48 months, and a secondary
patency of 77% for the 6 to 7 mm group for both 24 and 48
months (P .713; log rank). Finally, when comparing the
primary and secondary patency of the 6 to 7 mm stent graft
cohort versus the surgical group, the 6 to 7 mm stent graft
sizes have a slightly improved patency (62% vs. 58% primary
patency; 77% vs. 71% secondary patency).
Limb salvage was evaluated. There was one amputation
(98% limb salvage) in the stent graft cohort and six ampu-
tations (84% limb salvage) in the surgical group. All in-
stances of limb amputation occurred in patients that had
tissue loss preoperatively. Two amputations in the surgical
group were done for progressive tissue loss despite patent
bypass grafts. There is a significant difference in these two
groups (P  .039; Table XII [online only]). If the two
limbs in the surgical group that required amputation with
patent grafts are excluded, however, there is no statistically
significant difference in the amputation rate between these
two treatment groups (P  .131).
DISCUSSION
Treatment of SFA atherosclerotic disease with percuta-
neous transluminal angioplasty has shown to be effective in
short segment stenosis but has proved disappointing as a
primary treatment modality for longer segment disease and
total occlusions. Scott et al published a 3-year retrospective
review of 104 patients in 2007 demonstrating a 12, 24, and
36 month primary patency of 55%, 43%, and 35%, respec-
tively.23 The addition of self-expanding bare metal nitinol
stents has improved outcomes slightly for short to moder-
ate length arterial segments (4-12 cm) but also introduced
the problems of in-stent stenosis and stent fracture.24-26 A
stent fracture rate as high as 31% was recently reported in
the early results of the VIBRANT (Viabahn stent graft
versus bare nitinol stent) trial by Ansel and his collegues.27
Medicated stents designed to suppress in-stent restenosis
and improve overall patency have shown good promise but
are still somewhat early in their development, and late
results have shown failure to sustain reduction of in-stent
restenosis. The results reported by Lammer et al in the
STRIDES (A safety and efficacy study of the Dynalink-
Everolimus eluting peripheral stent system) study28 re-ported a primary patency at 12 months of 69% (80% by
target lesion revascularization [TLR]) at a lesion length of
only 9 cm. Dake and his colleagues reported excellent out-
comeswith paclitaxel combinedwith theZilver stent platform
(Cook Medical Inc, Bloomington, Ind) at 24 months with
reported clinically-driven patency of 82% in a registry arm
of the ongoing Zilver trial.29 Unfortunately, the patency in
this study is again reported only as TLR patency with a
moderate lesion length of 9.9 cm.
TASC classification in the current study demonstrates
approximately 60% of patients in both arms as TASC II B
and 25% to 30% as TASC II C or D lesions. Arterial
occlusions in the stent graft cohort were seen within all
TASC II classifications. Over two-thirds of all occlusions in
both groups were in the TASC II B classification, corre-
sponding to the group with the highest number of patients
overall. Endovascular treatment of TASC II C/D lesions
historically has a lower patency than that of TASC II A/B
lesions. This is not the case in the current study, although
there is an apparent trend towards that endpoint. There is
not shown to be any significant difference when endovas-
cular treatment is compared with surgical reconstruction
for these same lesions, although our patient cohort is small
for this type of analysis. The trends presented regarding
stent graft size suggest that larger diameter devices (5
mm) may have a better long term patency with stent graft
reconstruction unless newer modalities with heparin-
bonded technology or a more prolonged use of antiplatelet
agents can improve the patency of the smaller diameter
devices.
There remains concern among many that acute failure
and/or thrombosis of the stent graft will result in a higher
grade of ischemia at presentation, necessitating a more
complex/urgent surgical revascularization and/or even-
tual higher rate of limb loss.30 This point was not validated
in our study as we found no statistical difference in limb loss
between the two treatment modalities. Fifteen graft throm-
boses (16 graft failures) resulted in four below-knee ampu-
tations. Two additional amputations were performed in
patients with patent grafts for non-healing of ischemic foot
ulcers. Only one amputation in 18 stent graft failures was
required. Additionally, of those limbs requiring bypass
reconstruction for graft failure in the stent graft cohort,
64% were able to be performed above the knee. Concerns
often proposed about a higher rate of limb loss or “loss of
options” for above-knee reconstruction in the event of
stent graft failure are not supported.
There is an observed trend towards decreased patency
in patient limbs treated with the 5 mm stent grafts com-
pared to the 6 and 7 mm devices, although we found no
statistical difference in patency through 48months. Nine of
18 stent graft failures were in the 5 mm diameter graft
cohort but, due to the overall enrollment numbers in the 5
mm cohort vs the 6 to 7 mm cohort, the trend still exists
towards improved patency in the 6 to 7 mm group. If we
evaluate only the 6 and 7 mm stent graft patients indepen-
dently versus the femoral-popliteal bypass patients, the
trend of the primary and secondary patency of the stent
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popliteal bypass.
There are several recognized limitations to our study,
including a small total patient cohort and a single center
experience, although the outcomes demonstrated are com-
parable to previous reports.2-16 Although 37 of 40 (93%)
patients adhered to the recommended antiplatelet regimen
postoperatively in the stent graft arm, only 29 of 46 (63%)
patients in the surgical group were compliant with this
regimen. The initial study design was only intended to be
powered for a follow-up of 24 months as reported in our
previous series.1,17 Forty-eight month analysis allowed for
additional patients being lost to follow up and for some
who died (unrelated to revascularization in all cases), leav-
ing 32 of 50 limbs (64%) available for analysis in the stent
graft group and 26 of 50 limbs (52%) available in the
surgical group.
CONCLUSION
Our study demonstrates, through a prospective ran-
domized method, similar primary and secondary patency
rates for all TASC II lesions (A-D) in the use of percutane-
ously placed stent grafts versus surgically placed synthetic
conduit in the SFA at up to 48months. Our initial technical
success rate of 100% and our primary and secondary pa-
tency rates in both arms mirrors that of numerous previ-
ously published reports.2-16,31,32 It is our feeling that, for
longer SFA lesions/occlusions (over 10 cm), the stent graft
data presented herein and among other authors2-16 sup-
ports improved outcomes when compared with available
published reports of other currently available modalit-
ies23-29, 33-40 if endovascular is being considered. We be-
lieve that percutaneous stent graft placement in the SFA
may be considered as first line treatment for long SFA
lesions, especially if autologous conduit is unavailable.
AUTHOR CONTRIBUTIONS
Conception and design: BT, DG
Analysis and interpretation: SB, DG, GP
Data collection: KM, DG
Writing the article: KM, DG
Critical revision of the article: KM, DG, GP
Final approval of the article: BT, KM, DG, GP
Statistical analysis: SB
Obtained funding: BT, DG
Overall responsibility: DG
REFERENCES
1. McQuade K, Gable D, MD, Hohman S, Pearl G, Theune B. Two-year
randomized prospective comparison of percutaneous ePTFE/nitinol
self-expanding stent graft vs prosthetic femoral-popliteal bypass in the
treatment of superficial femoral artery occlusive disease. J Vasc Surg
2008;49:109-16.
2. Lammer J, Dake MD, Bleyn J, Katzen B, Cejna M, Piquet P, et al. for
the International Trial Study Group. Peripheral arterial obstruction:
prospective study of treatment with a transluminally placed self-expanding
stent graft. Radiology 2000;217:95-104.
3. Railo M, Roth W, Edgren J, Biancari F, Ikonen T, Albäck A, Lepäntalo
M. Preliminary results with endoluminal femoropopliteal thrupass. Ann
Chir Gynaecol 2001;90:15-8.4. Jahnke T, Andresen R, Müller-Hülsbeck S, Schafer F, Voshage G,
HellerM, et al. Hemobahn stent grafts for treatment of femoropopliteal
arterial obstructions: midterm results of a prospective trial. J Vasc Interv
Radiol 2003;14:41-51.
5. Turicchia G, Cevolani M, Altini R, Stancanelli V. Mid-term results in
PTFE endograft treatment of femoropopliteal occlusive disease. Osp
Ital Chir 2003;9:93-6.
6. Bleyn J, Schol F, Vanhandenhove I, Vercaeren P, Marien C. Endovas-
cular reconstruction of the superficial femoral artery. In: Becquemin JP,
Alimi YS, Watelet J, Loisance D, editors. Controversies and updates in
vascular and cardiac surgery. Torino, Italy:Edizioni Minerva Medica
2004. Vol. 14, pp. 87-91.
7. Panetta T. Endovascular femoropopliteal bypass with multiple stent
grafts. Endovascular Today 2005;4:Supplement:12-4.
8. Chopra P. Endoluminal femoropopliteal bypass using the Viabahn
Stent Graft (Endograft): primary and secondary patency in 60 patients
(70 limbs) with 3-year follow-up. Abstract presented at the 14th Annual
Advanced Interventional Management Symposium. (AIMS) November
13-16, 2006. New York, NY. Page II 2.1.
9. Coats R, Adams J Jr, Humphrey P. SFA revascularization using the
Viabahn Endoprosthesis. Endovascular Today 2006;5:76-8.
10. Fischer M, Schwabe C, Schulte K-L. Value of the Hemobahn/Viabahn
Endoprosthesis in the treatment of long chronic lesions of the superfi-
cial femoral artery: 6 years of experience. J Endovasc Ther 2006;13:
281-90.
11. Zander T, Llorens R, Rostagno R, Zerolo I, Rabellino N, Maynar M.
Hemobahn/Viabahn endograft for long SFA lesions. Long term follow
up. J Vasc Interv Radiol 2006;17(2)Part 2:S57.
12. Saxon R, Coffman J, Gooding J, Ponec D. Long term patency of stent
grafts in the treatment of long-segment femoropopliteal artery occlusive
disease. J Vasc Interv Radiol 2006;18:1341-50.
13. Alimi Y, Hakam Z, Hartung O, Boufi M, Barthelelmy M, Aissi K, et al.
Efficacy of Viabahn in the treatment of severe superficial artery lesions:
which factors influence long-term patency? Eur J Vasc Endovasc Surg
2008;35:346-52.
14. Djelmami-Hani M. Presented at ACC/SCAI Meeting March 29- April
1, 2008, Chicago, Ill.
15. Saxon RR, Dake MD, Vogelzang RL, Katzen BT, Becker GJ. Random-
ized, multicenter study comparing expanded polytetrafluoroethelene-
covered endoprosthesis placement with percutaneous transluminal an-
gioplasty in the treatment of superficial femoral artery occlusive disease.
J Vasc Interv Radiol 2008;19:823-32.
16. Verta M, Schneider, J, Alonzn M, Hahn D. Percutaneous-Viabahn
assisted subintimal recannalization for severe superficial artery occlusive
disease. J Vasc Interv Radiol 2008;19:493-8.
17. Kedora J, Hohmann S, Garrett W, Munschaur C, Theune B, Gable D.
Randomized comparison of percutaneous Viabahn Stent grafts versus
prosthetic femoral-popliteal bypass in the treatment of superficial fem-
oral arterial occlusive disease. J Vasc Surg 2007;45:10-6.
18. Ahn S, Rutheford R, Becker G, Camerota A, Johnston K, McClean G,
et al. Reporting standards for lower extremity arterial endovascular
procedures. J Vasc Surg 1993;17:1103-7.
19. Rutherford R, Baker D, Ernst C, Johnston K, Porter J, Ahn S. Recom-
mended standards for reports dealing with lower extremity ischemia:
revised version. J Vasc Surg 1997;26:517-38.
20. Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F, et al
on behalf of the TASC II Working Group. Inter-Society Consensus for
the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg
2007;45(suppl):S5-S67.
21. Rutherford R, Baker D, Ernst C, Ahn S, Jones D. Recommended
standards for reports dealing with lower extremity ischemia: Rutherford
version. J Vasc Surg 1997;26:517-38.
22. Norgen L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes
FG, et al; TASC II Working Group. Inter-society consensus for the
management of peripheral arterial disease. Int Angiology 2007;26:81-
157.
23. Scott E, Biuckians A, Light R, Scibelli C, Milner T, Meier G, Panneton
J. Subintimal angioplasty for the treatment of claudication and critical
limb ischemia: 3-year results. J Vasc Surg 2007;46:959-64.
JOURNAL OF VASCULAR SURGERY
September 2010590 McQuade et al24. Schlager O, Dick P, Sabeti S, Amighi J, Miekusch W, Minar E, Schill-
inger M. Long segment SFA stenting-the dark sides: in stent restenosis,
clinical deterioration, and stent fractures. J Endovasc Ther 2005;12:
676-84.
25. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Miekusch W, et al.
Ballon angioplasty versus implantation of nitinol stents in the superficial
femoral artery. N Engl J Med 2006;354:1879-88.
26. Krankenberg H, Schluter M, Steinkamp H, Burgelin K, Scheinert D,
Schulte K, et al. Nitinol stent implantation versus percutaneous trans-
luminal angioplasty in superficial femoral artery lesions up to 10 cm in
length: the femoral artery stenting trial (FAST). Circulation 2007;116:
285-92.
27. Ansel G. Interim 1-year VIBRANT resultspresented for Gore Viabahn
in SFA treatment. Presented at Vascular Interventional Advances, Las
Vegas, Nevada, October 22, 2009.
28. Lammer J, Schillinger M, Zeller T, Boone E, Zaugg M, Verta P,
Schwartz L. First-in-human clinical trial of a nitinol self-expanding
everolimus-eluting stent for prevention of restenosis following infrain-
guinal endovascular intervention: the STRIDES trial. Presented at
CIRSE, Lisbon, Portugal, Sept. 19-23, 2009.
29. Dake M. Two-Year Results of the ZILVER-PTX Drug-Eluting Stent
for SFA Lesions. Presented at Veith Symposium New York, New York,
November 19, 2009.
30. Joels C, York J, Kalbaugh C, Cull D, Langan E, Taylor S. Surgical
implications of early failed endovascular intervention of the superficial
femoral artery. J Vasc Surg 2008;47:562-65.
31. Dorrucci V. Treatment of superficial femoral artery occlusive disease.
J Cardiovasc Surg 2004;45:193-201.
32. Bates M, Aburahma A. An update on endovascular therapy of the lower
extremities. J Endovasc Ther 2004;11suppl 2:II107-27.
33. Bosiers M, Torsello G, Gibler H, Ruef J, Muller-Hulsbeck S, JahnkeT,
et al. Nitinol stent implantation in long superficial femoral artery
VIBRANT trial, which you referred to in your manuscript,lesions: 12-month results of the DURABILITY I study. J Endovasc
Ther 2009;16:261-69.
34. Krankenberg H, Schluter M, Steinkamp H, Burglin K, Scheinart D,
Schulte K, et al. Nitinol stent implantation versus percutaneous trans-
luminal angioplastyin superficial femoral artery lesions up to 10 cm in
length: the femoral artery stenting trial (FAST). Circulation 2007;
116:285-92.
35. Kazemi S, Bangash A, Djebmami-Hani M, Gupta A, Tumuburi R,
Shalev Y, et al. Prospective randomized comparison of Viabahn stent
graft versus SIlverhawk atherectomy for denovofemoralpopliteal occlu-
sive disease (abstract only). Presented at TCT Oct 23, 2006.
36. Zeller T, Rastan A, Sixt S, Schwarzwalder U, Schwarz T, Frank U, et al.
Long-term results after directional atherectomy of femoro-popliteal
lesions. J Am Coll Cardiol 2006;48:1573-8.
37. Samson R, Showalter D, Lepore JR M, Nair D, Merigliono, K. Cryo-
plasty therapy of the superficial femoral and popliteal arteries: a reap-
praisal after 44 months’ experience. J Vasc Surg 2008;48:634-7.
38. Schillinger M, Sabeti S, Dick P, Amidhi J, Mlekusch W, Schlager O, et
al. Sustained benefit at 2 years of primary femoropopliteal stenting
compared with balloon angioplasty with optional stenting. Circulation
2007;115:2745-9.
39. Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, et al.
Balloon angioplasty versus stenting with nitinol stents in intermediate
length superficial femoral artery lesions. Catheter Cardiovasc Interv
2009;74:1090-5.
40. Schillinger M, Sebeti S, Loewe C, Dick P, Amighi J, Mlkusch W, et al.
Balloon angioplasty versus implantation of nitinol stents in the superfi-
cial femoral artery. N Engl J Med 2006;354:1879-88.
Submitted Jan 22, 2010; accepted Mar 30, 2010.
Additional material for this article may be found online
at www.jvascsurg.org.DISCUSSION
Dr John F. Eidt (Little Rock, Ark). This is indeed a unique
randomized trial comparing above knee synthetic bypass to the
Gore stent graft. Of note, the authors report comparable perfor-
mance between these two treatment groups at 4 years. There is a
trend favoring stent grafts larger than 5 mm in diameter.
There are still important questions regarding endograft treat-
ment of the SFA. 1) Stent grafts result in the loss of all collateral
vessels in the covered segment. 2) The unsheathed design exposes
the relatively rough outer texture of the delivery system to the
arterial wall, may result in so-called “snow-plowing,” and may risk
damage to the draw string release mechanism. 3) For entry into
this trial, flush occlusions of the SFA were excluded, which elimi-
nates one of the issues with Viabahn related to precise location of
the proximal end of the stent graft in proximity to the profunda
femoris. 4) Some surgeons have been concerned that thrombosis
of the stent graft may result in deterioration of runoff with a need
for more distal target at the time of conversion – a worry that was
not substantiated by your data. 5) You have noted in your manu-
script a higher amputation rate in the bypass group though, in
fairness, in two cases the grafts remained patent at the time of
amputation. In addition, there were more than twice as many
Rutherford class 4, 5, and 6 patients in the bypass arm of the trial
(9 vs 19). 6) There were a variety of antithrombotic regimens;
almost all (93%) of the stent graft patients were on combination
antiplatelet therapy with aspirin and plavix in comparison to only
about half of the bypass patients.
I have three questions:
1. The patients included in this trail had relatively mild lesions.
More than 70%were TASC II A and B lesions, meaning that the
maximum length was less than 15 cm. The Resilient trial
documented 12-month patency of more than 80% for a bare
nitinol stents in TASC A and B lesions. Further, in thethere was no difference between bare nitinol stents and Viabahn
at 1 year with primary patency of only around 55%. My ques-
tion: is Viabahn better than bare nitinol? Is it worth the addi-
tional cost?
2. You also have shown statistically what many have us have
observed; if you get through the first year or so, you are likely to
de well long-term. When grafts fail, it appears to be unpredict-
able. What is your current recommendation for ultrasound
surveillance in these patients? Did you identify failing grafts and
intervene prior to graft failure?
3. If I understand your numbers, of the 46 bypass patients, 15
were lost to follow up and 8 died leaving 23 patients. Of these,
there were 16 graft failures. In the stent graft group, of 40
patients, 6 were lost and 9 died, leaving 25 patients with 18
stent graft failures. Now it is possible that all those lost to follow
up were lost because they were doing well, but I suspect that at
least some of these patients wound up in the offices of other
vascular surgeons. In a population of predominately TASC A
and B lesions with mostly intermittent claudication, are these
results really good enough?
Dr Karen McQuade (Dallas, Tex). Thank you, Dr Eidt, for
your questions. To answer your first question, yes, we did exclude
flush occlusions. The patient had to have at least 1 cm of good
artery proximally for stent graft landing. The second question
addressed our TASC classification. I would point out that we
initially enrolled and we did use TASC I classification for our target
lesions characteristics, but here in our follow-up study, we have
used TASC II criteria, and remember, a TASC II B lesion can
include occlusions up to 15 cm, so a lot of these patients would
have been a TASC I C or D classification, whereas they have now
have been reclassified as a Class II B lesion. I think that many
studies are currently still using TASC I criteria for their classifica-
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 3 McQuade et al 591tion reporting so that might explain some of the difference there.
The RESILIANT study addressed much shorter lesions less than
10 cm at only 24-month follow up.
For follow-up purposes, we followed these patients every 3
months with duplex ultrasound for the first year, then every 6
months if there were no identified issues. Any graft identified with
a significant stenosis was reported as a failure, so none of the patent
grafts were intervened on. One of your questions discussed the use
of our stent grafts and claudicants. In our practice, we do recom-recommend best medical management, exercise therapy, and
smoking cessation for claudicants; however, for those patients who
fail these modalities or who are unable to perform their activities in
daily living, we consider intervention on these patients, and we do
give consideration to reconstruction with stent grafts for these
patients. I believe in terms of whether our patency rates we are
reporting here are good enough, I think that each patient is an
individual, that each treating physician is an individual, and we
offer this data for you to use in your decision making for treatmentmend initially non-interventional treatment for claudicants. We of these patients.
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Rutherford chronic limb ischemia categories19
Clinical grade
Stent graft
limbs N  50
Surgical bypass
limbs N  50
0 0 0
1 2 1
2 23 20
3 16 10
4 4 10
5 4 7
6 1 2
Generalized Fisher’s exact test, P  .367.
Table VI. Online only. Number of run-off vessels by
stent graft size
Stent graft size 5 mm 6-7 mm Total patients
1 8 5 13 (26%)
2 4 12 16 (32%)
3 9 12 21 (42%)
Total patients 21 29 50 (100.0%)
Fisher’s exact test P  .157.
Table VII. Online only. Run-off score by stent graft
size
Run-off score by
stent graft size 5 mm 6-7 mm Total patients
1 9 12 21 (42%)
2 0 0 0 (0.0%)
3 0 0 0 (0.0%)
4 4 11 15 (30.0%)
5 0 0 0 (0.0%)
6 0 1 1 (2.0%)
7 8 5 13 (26.0%)
Total patients 21 29 50 (100.0%)
Fisher’s exact test P  .214.
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Time post-treatment (days)
N at risk at
start of interval
N events during
interval*
N censored
during interval*
% free from
loss of patency
95% confidence
interval
Group: femoropopliteal bypass
0 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 50 1 (1) 4 (4) 0.980 (0.866, 0.997)
(31-137) 45 2 (3) 2 (6) 0.935 (0.812, 0.979)
(137-228) 41 4 (7) 4 (10) 0.837 (0.686, 0.919)
(228-320) 33 1 (8) 0 (10) 0.811 (0.656, 0.901)
(320-410) 32 2 (10) 0 (10) 0.760 (0.599, 0.864)
(410-593) 30 3 (13) 0 (10) 0.684 (0.518, 0.804)
(593-730) 27 2 (15) 0 (10) 0.634 (0.466, 0.761)
(730-1095) 25 0 (15) 13 (23) 0.634 (0.466, 0.761)
(1095-1460) 12 1 (16) 3 (26) 0.581 (0.396, 0.727)
Group: stent graft
0 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 50 1 (1) 0 (0) 0.980 (0.866, 0.997)
(31-137) 49 6 (7) 4 (4) 0.857 (0.722, 0.929)
(137-228) 39 2 (9) 1 (5) 0.813 (0.670, 0.898)
(228-320) 36 4 (13) 0 (5) 0.722 (0.569, 0.829)
(320-410) 32 0 (13) 0 (5) 0.722 (0.569, 0.829)
(410-593) 32 3 (16) 3 (8) 0.654 (0.497, 0.772)
(593-730) 26 1 (17) 3 (11) 0.627 (0.468, 0.750)
(730-1095) 22 0 (17) 7 (18) 0.627 (0.468, 0.750)
(1095-1460) 15 1 (18) 0 (18) 0.585 (0.416, 0.721)Log rank P value: P  .807.
*Number in parenthesis represents cumulative events or censored observations through end of interval.Table IX. Online only. Secondary patency by treatment group
Time post-treatment (days)
N at risk at
start of interval
N events
during interval*
N censored
during interval*
% free from
loss of patency
95% confidence
interval
Group: femoropopliteal bypass
0 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 50 1 (1) 4 (4) 0.980 (0.866, 0.997)
(31-137) 45 1 (2) 2 (6) 0.957 (0.839, 0.989)
(137-228) 42 3 (5) 4 (10) 0.884 (0.742, 0.950)
(228-320) 35 1 (6) 0 (10) 0.859 (0.711, 0.934)
(320-410) 34 0 (6) 0 (10) 0.859 (0.711, 0.934)
(410-593) 34 2 (8) 1 (11) 0.808 (0.652, 0.899)
(593-730) 31 2 (10) 0 (11) 0.756 (0.593, 0.861)
(730-1095) 29 0 (10) 13 (24) 0.756 (0.593, 0.861)
(1095-1460) 16 1 (11) 5 (29) 0.709 (0.525, 0.832)
Group: stent graft
0 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(31-137) 50 5 (5) 4 (4) 0.899 (0.773, 0.957)
(137-228) 41 2 (7) 1 (5) 0.855 (0.719, 0.928)
(228-320) 38 1 (8) 0 (5) 0.832 (0.692, 0.913)
(320-410) 37 0 (8) 0 (5) 0.832 (0.692, 0.913)
(410-593) 37 3 (11) 3 (8) 0.764 (0.614, 0.862)
(593-730) 31 1 (12) 3 (11) 0.738 (0.583, 0.843)
(730-1095) 27 0 (12) 11 (22) 0.738 (0.583, 0.843)
(1095-1460) 16 0 (12) 1 (23) 0.738 (0.583, 0.843)
Log rank P value: P  .891.
*Number in parenthesis represents cumulative events or censored observations through end of interval.
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Broken lines indicate patency with standard error 10%. Log-rank P value: P  .484.
Days 0 31 137 228 320 410 593 730 1095 1460
5 mm stent graft 21 21 20 15 13 11 11 9 8 5
6-7 mm Stent graft 29 29 29 24 23 21 21 17 14 10
Femoral-popliteal bypass 50 50 45 41 33 32 30 27 25 12
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Time post-treatment (days)
N at risk at
start of interval
N events
during interval*
N censored
during interval*
% free from
loss of patency
95% confidence
interval
Group: femoropopliteal bypass
0 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 50 1 (1) 4 (4) 0.980 (0.866, 0.997)
(31-137) 45 2 (3) 2 (6) 0.935 (0.812, 0.979)
(137-228) 41 4 (7) 4 (10) 0.837 (0.686, 0.919)
(228-320) 33 1 (8) 0 (10) 0.811 (0.656, 0.901)
(320-410) 32 2 (10) 0 (10) 0.760 (0.599, 0.864)
(410-593) 30 3 (13) 0 (10) 0.684 (0.518, 0.804)
(593-730) 27 2 (15) 0 (10) 0.634 (0.466, 0.761)
(730-1095) 25 0 (15) 13 (23) 0.634 (0.466, 0.761)
(1095-1460) 12 1 (16) 3 (26) 0.581 (0.396, 0.727)
Group: stent graft 5 mm
0 21 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 21 1 (1) 0 (0) 0.952 (0.707, 0.993)
(31-137) 20 4 (5) 1 (1) 0.762 (0.519, 0.893)
(137-228) 15 1 (6) 1 (2) 0.711 (0.466, 0.859)
(228-320) 13 2 (8) 0 (2) 0.602 (0.357, 0.779)
(320-410) 11 0 (8) 0 (2) 0.602 (0.357, 0.779)
(410-593) 11 0 (8) 2 (4) 0.602 (0.357, 0.779)
(593-730) 9 1 (9) 0 (4) 0.535 (0.290, 0.729)
(730-1095) 8 0 (9) 3 (7) 0.535 (0.290, 0.729)
(1095-1460) 5 0 (9) 0 (7) 0.535 (0.290, 0.729)
Group: stent graft 6-7 mm
0 29 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 29 0 (0) 0 (0) 1.000 (1.000, 1.000)
(31-137) 29 2 (2) 3 (3) 0.924 (0.730, 0.981)
(137-228) 24 1 (3) 0 (3) 0.886 (0.687, 0.962)
(228-320) 23 2 (5) 0 (3) 0.809 (0.600, 0.916)
(320-410) 21 0 (5) 0 (3) 0.809 (0.600, 0.916)
(410-593) 21 3 (8) 1 (4) 0.691 (0.476, 0.832)
(593-730) 17 0 (8) 3 (7) 0.691 (0.476, 0.832)
(730-1095) 14 0 (8) 4 (11) 0.691 (0.476, 0.832)
(1095-1460) 10 1 (9) 0 (11) 0.622 (0.386, 0.789)Log rank P value: P  .484.
*Number in parenthesis represents cumulative events or censored observations through end of interval.
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 3 McQuade et al 591.e5Fig 4. Online only.
Broken lines indicate patency with standard error 10%. Log-rank P value: P  .713.
Days 0 31 137 228 320 410 593 730 1095 1460
5 mm stent graft 21 21 21 16 14 14 14 12 11 5
6-7 mm stent graft 29 29 29 25 24 23 23 19 16 11
Femoral-popliteal bypass 50 50 45 42 35 34 34 31 29 16
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Time post-treatment (days)
N at risk at
start of interval
N events
during interval*
N censored
during interval*
% free from
loss of patency
95% confidence
interval
Group: femoropopliteal bypass
0 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 50 1 (1) 4 (4) 0.980 (0.866, 0.997)
(31-137) 45 1 (2) 2 (6) 0.957 (0.839, 0.989)
(137-228) 42 3 (5) 4 (10) 0.884 (0.742, 0.950)
(228-320) 35 1 (6) 0 (10) 0.859 (0.711, 0.934)
(320-410) 34 0 (6) 0 (10) 0.859 (0.711, 0.934)
(410-593) 34 2 (8) 1 (11) 0.808 (0.652, 0.899)
(593-730) 31 2 (10) 0 (11) 0.756 (0.593, 0.861)
(730-1095) 29 0 (10) 13 (24) 0.756 (0.593, 0.861)
(1095-1460) 16 1 (11) 5 (29) 0.709 (0.525, 0.832)
Group: stent graft 5 mm
0 21 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 21 0 (0) 0 (0) 1.000 (1.000, 1.000)
(31-137) 21 4 (4) 1 (1) 0.810 (0.569, 0.924)
(137-228) 16 1 (5) 1 (2) 0.759 (0.514, 0.892)
(228-320) 14 0 (5) 0 (2) 0.759 (0.514, 0.892)
(320-410) 14 0 (5) 0 (2) 0.759 (0.514, 0.892)
(410-593) 14 0 (5) 2 (4) 0.759 (0.514, 0.892)
(593-730) 12 1 (6) 0 (4) 0.696 (0.439, 0.852)
(730-1095) 11 0 (6) 6 (10) 0.696 (0.439, 0.852)
(1095-1460) 5 0 (6) 0 (10) 0.696 (0.439, 0.852)
Group: stent graft 6-7 mm
0 29 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 29 0 (0) 0 (0) 1.000 (1.000, 1.000)
(31-137) 29 1 (1) 3 (3) 0.963 (0.765, 0.995)
(137-228) 25 1 (2) 0 (3) 0.924 (0.730, 0.981)
(228-320) 24 1 (3) 0 (3) 0.886 (0.687, 0.962)
(320-410) 23 0 (3) 0 (3) 0.886 (0.687, 0.962)
(410-593) 23 3 (6) 1 (4) 0.768 (0.555, 0.889)
(593-730) 19 0 (6) 3 (7) 0.768 (0.555, 0.889)
(730-1095) 16 0 (6) 5 (12) 0.768 (0.555, 0.889)
(1095-1460) 11 0 (6) 1 (13) 0.768 (0.555, 0.889)Log rank P value: P  .713.
*Number in parenthesis represents cumulative events or censored observations through end of interval.
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Time post-treatment (months)
N at risk at
start of interval
N events during
interval*
N censored
during interval*
% free from
loss of limb
95% confidence
interval
Group: femoropopliteal bypass
0 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 50 2 (2) 3 (3) 0.960 (0.849, 0.990)
(31-137) 45 1 (3) 1 (4) 0.938 (0.820, 0.980)
(137-228) 43 1 (4) 4 (8) 0.914 (0.786, 0.967)
(228-320) 38 1 (5) 0 (8) 0.890 (0.755, 0.953)
(320-410) 37 0 (5) 0 (8) 0.890 (0.755, 0.953)
(410-593) 37 0 (5) 1 (9) 0.890 (0.755, 0.953)
(593-730) 36 0 (5) 1 (10) 0.890 (0.755, 0.953)
(730-1095) 35 0 (5) 16 (26) 0.890 (0.755, 0.953)
(1095-1460) 19 1 (6) 5 (31) 0.843 (0.667, 0.931)
Group: stent graft
0 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(0-31) 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
(31-137) 50 1 (1) 4 (4) 0.980 (0.866, 0.997)
(137-228) 45 0 (1) 1 (5) 0.980 (0.866, 0.997)
(228-320) 44 0 (1) 0 (5) 0.980 (0.866, 0.997)
(320-410) 44 0 (1) 0 (5) 0.980 (0.866, 0.997)
(410-593) 44 0 (1) 3 (8) 0.980 (0.866, 0.997)
(593-730) 41 0 (1) 4 (12) 0.980 (0.866, 0.997)
(730-1095) 37 0 (1) 11 (23) 0.980 (0.866, 0.997)
(1095-1460) 26 0 (1) 3 (26) 0.980 (0.866, 0.997)Log rank P value: P  .039.
*Number in parenthesis represents cumulative events or censored observations through end of interval.
